The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 765K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

46 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
13
Discovery of KDM5A inhibitors: Homology modeling, virtual screening and structure-activity relationship analysis.EBI
Sichuan University
78
Recent Progress in Histone Demethylase Inhibitors.EBI
University of Oxford
6
Inhibition of Histone Demethylases Offers a Novel and Promising Approach for the Treatment of Cancer and Other Diseases.EBI
Therachem Research Medilab (India)
34
Docking and Linking of Fragments To Discover Jumonji Histone Demethylase Inhibitors.EBI
University of Oxford
56
8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors.EBI
The Institute of Cancer Research
14
Novel mechanistic insights - A brand new Era for anti-HBV drugs.EBI
Peking University
4
Inhibition of demethylases by GSK-J1/J4.EBI
EpiTherapeutics Aps
4
Discovery of an efficacious KDM5B PROTAC degrader GT-653 up-regulating IFN response genes in prostate cancer.EBI
East China Normal University
8
Structural optimization of a lysine demethylase 5 inhibitor for improvement of its cellular activity.EBI
Osaka University
38
Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy.EBI
Zhengzhou University
11
Phenyl-quinoline-xxo-butyric Acid Inhibitors of Histone Lysine Demethylase for the Treatment of Cancer.EBI
Arrival Discovery
57
Discovery of a novel 1H-pyrazole- [3,4-b] pyridine-based lysine demethylase 5B inhibitor with potential anti-prostate cancer activity that perturbs the phosphoinositide 3-kinase/AKT pathway.EBI
Zhengzhou University
18
Focused Screening Identifies Different Sensitivities of Human TET Oxygenases to the Oncometabolite 2-Hydroxyglutarate.EBI
University of Oxford
43
Pharmacological inhibition of KDM5A for cancer treatment.EBI
Ningbo University
34
Targeting histone demethylase KDM5B for cancer treatment.EBI
Zhengzhou University
17
Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors.EBI
University of Oxford
44
Recent Advances with KDM4 Inhibitors and Potential Applications.EBI
St. Jude Children'S Research Hospital
33
Discovery of Novel Pyrazole-Based KDM5B Inhibitor EBI
Zhengzhou University
13
First-in-Class Inhibitors of the Ribosomal Oxygenase MINA53.EBI
University of Oxford
36
Discovery of pyrazole derivatives as cellular active inhibitors of histone lysine specific demethylase 5B (KDM5B/JARID1B).EBI
Zhengzhou University
9
Lysine demethylase 5B (KDM5B): A potential anti-cancer drug target.EBI
Zhengzhou University
15
Design and evaluation of 1,7-naphthyridones as novel KDM5 inhibitors.EBI
Genentech
20
Identification of potent, selective KDM5 inhibitors.EBI
Constellation Pharmaceuticals
43
Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies.EBI
Genentech
7
Identification of novel lysine demethylase 5-selective inhibitors by inhibitor-based fragment merging strategy.EBI
Kyoto Prefectural University of Medicine
34
C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays.EBI
Institute of Cancer Research
35
Structure-based design and discovery of potent and selective KDM5 inhibitors.EBI
Celgene
7
Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer Models.EBI
Celgene Quanticel Research
39
From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.EBI
Genentech
19
N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitorsBDB
University of Michigan
55
Indole derivatives and their use as protein kinase inhibitorsBDB
Respivert
15
Acetyl-CoA carboxylase modulatorsBDB
Monsanto Technology
189
Pyrido five-element aromatic ring compound, preparation method therefor and use thereofBDB
Shanghai Haihe Pharmaceutical
168
Imidazopyrrolidine derivatives and their use in the treatment of diseaseBDB
Novartis
119
Polyfluorinated compounds acting as bruton tyrosine kinase inhibitorsBDB
Zhejiang Dtrm Biopharma
10
Inhibitors of c-fms kinaseBDB
Janssen Pharmaceutica
5
Substituted heteroaryl compounds and methods of useBDB
Calitor Sciences
7
Steroidal 5a-reductase inhibitors using 4-androstenedione as substrate.BDB
Metropolitan University-Xochimilco
10
Roles of phosphate recognition in inositol 1,3,4,5,6-pentakisphosphate 2-kinase (IPK1) substrate binding and activation.BDB
Mcgill University
15
Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activitiesBDB
Almirall
4
A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate.BDB
Whitehead Institute For Biomedical Research
26
5-HT3 receptor modulators, methods of making, and use thereofBDB
Albany Molecular Research
12
Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitorsBDB
Merck Sharp & Dohme
3
Identification of the molecular mechanisms by which the diterpenoid salvinorin A binds to kappa-opioid receptors.BDB
Case Western Reserve University